| LUNG NSCLC Adjuvant - cISplatin and vinORELBine Q3W | 1.0.0 | 26/07/2024 |
| LUNG NSCLC Adjuvant - cISplatin and vinORELBine Q4W | 1.0.0 | 26/07/2024 |
| LUNG NSCLC Adjuvant - osimertinib | 1.0.0 | 28/03/2023 |
| LUNG NSCLC Definitive - [Superior sulcus Pancoast] cISplatin and etoposide chemoradiation | 3.0.0 | 26/07/2024 |
| LUNG NSCLC Definitive - cARBOplatin and PACLItaxel chemoradiation | 2.0.0 | 01/08/2024 |
| LUNG NSCLC Definitive - cISplatin and etoposide chemoradiation | 3.0.0 | 26/07/2024 |
| LUNG NSCLC Definitive - cISplatin and gemcitabine chemoradiation | 1.0.0 | 26/07/2024 |
| LUNG NSCLC Definitive - cISplatin and pemetrexed chemoradiation | 1.0.0 | 18/09/2024 |
| LUNG NSCLC Definitive - cISplatin and vinBLASTine chemoradiation | 1.0.0 | 26/07/2024 |
| LUNG NSCLC Locally advanced - durvalumab Q2W [weight based dosing] | 1.0.0 | 17/10/2022 |
| LUNG NSCLC Locally advanced - durvalumab Q4W [flat dosing] | 1.0.0 | 28/03/2023 |
| LUNG NSCLC Locally advanced/Metastatic - alectinib | 1.0.0 | 18/08/2024 |
| LUNG NSCLC Locally advanced/Metastatic - aTEZOLIzumab Q3W | 1.0.0 | 18/08/2024 |
| LUNG NSCLC Locally advanced/Metastatic - brigatinib | 1.0.0 | 18/08/2024 |
| LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and gemcitabine | 1.0.0 | 05/07/2023 |
| LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and vinORELBine | 1.0.0 | 05/07/2023 |
| LUNG NSCLC Locally advanced/Metastatic - crizotinib | 1.0.0 | 18/08/2024 |
| LUNG NSCLC Locally advanced/Metastatic - Enhertu [trastuzumab deruxtecan] | 1.0.0 | 05/09/2024 |
| LUNG NSCLC Locally advanced/Metastatic - entrectinib | 1.0.0 | 18/08/2024 |
| LUNG NSCLC Locally advanced/Metastatic - lorlatinib | 1.0.0 | 18/08/2024 |
| LUNG NSCLC Locally advanced/Metastatic - osimertinib | 1.0.0 | 30/09/2024 |
| LUNG NSCLC Locally advanced/Metastatic - pralsetinib | 1.0.0 | 18/08/2024 |
| LUNG NSCLC Metastatic - aFATinib | 1.0.0 | 27/07/2021 |
| LUNG NSCLC Metastatic - cARBOplatin and DOCEtaxel | 2.0.0 | 05/07/2022 |
| LUNG NSCLC Metastatic - cARBOplatin and PACLItaxel | 3.0.0 | 28/03/2023 |
| LUNG NSCLC Metastatic - cARBOplatin and pemetrexed | 3.0.0 | 29/10/2023 |
| LUNG NSCLC Metastatic - cARBOplatin and Q1W PACLItaxel | 2.0.0 | 19/09/2023 |
| LUNG NSCLC Metastatic - cARBOplatin, PACLItaxel and pembrolizumab | 3.0.0 | 28/03/2023 |
| LUNG NSCLC Metastatic - cARBOplatin, PACLItaxel, aTEZOLIzumab and beVACizumab | 3.0.0 | 28/03/2023 |
| LUNG NSCLC Metastatic - cARBOplatin, pemetrexed and pembrolizumab | 3.0.0 | 29/10/2023 |
| LUNG NSCLC Metastatic - cISplatin and gemcitabine | 1.0.0 | 12/05/2022 |
| LUNG NSCLC Metastatic - cISplatin and pemetrexed | 2.0.0 | 29/10/2023 |
| LUNG NSCLC Metastatic - cISplatin and vinORELBine | 1.0.0 | 30/11/2021 |
| LUNG NSCLC Metastatic - daBRAFEnib and tRAMEtinib | 3.0.0 | 17/10/2022 |
| LUNG NSCLC Metastatic - DOCEtaxel Q1W | 1.0.0 | 06/08/2021 |
| LUNG NSCLC Metastatic - DOCEtaxel Q3W | 1.0.0 | 06/08/2021 |
| LUNG NSCLC Metastatic - erlotinib | 1.0.0 | 30/11/2021 |
| LUNG NSCLC Metastatic - gefitinib | 1.0.0 | 30/11/2021 |
| LUNG NSCLC Metastatic - gemcitabine | 2.0.0 | 29/10/2023 |
| LUNG NSCLC Metastatic - nivolumab Q2W [flat dosing] | 3.0.0 | 17/10/2022 |
| LUNG NSCLC Metastatic - nivolumab Q2W [weight based dosing] | 1.0.0 | 27/07/2021 |
| LUNG NSCLC Metastatic - nivolumab Q4W [flat dosing] | 3.0.0 | 17/10/2022 |
| LUNG NSCLC Metastatic - PACLItaxel Q1W | 3.0.0 | 28/03/2023 |
| LUNG NSCLC Metastatic - pembrolizumab Q3W [flat dosing] | 1.0.0 | 28/03/2023 |
| LUNG NSCLC Metastatic - pembrolizumab Q6W [flat dosing] | 1.0.0 | 18/08/2024 |
| LUNG NSCLC Metastatic - vinORELBine [oral] 60 [day 1 and 8] Q3W | 1.0.0 | 18/09/2024 |
| LUNG NSCLC Metastatic - vinORELBine [oral] 60 Q1W | 1.0.0 | 18/09/2024 |
| LUNG NSCLC Metastatic - vinORELBine 25 Q1W | 1.0.0 | 19/04/2023 |
| LUNG NSCLC Metastatic - vinORELBine 30 [day 1 and 8] Q3W | 1.0.0 | 19/04/2023 |
| LUNG NSCLC Neoadjuvant - cISplatin, gemcitabine and nivolumab | 1.0.0 | 18/08/2024 |
| LUNG NSCLC Neoadjuvant - cISplatin, pemetrexed and nivolumab | 1.0.0 | 18/08/2024 |
